CoChat

Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease

Open access
Gutsaeva, Diana R., Parkerson, James B., Yerigenahally, Shobha D., Kurz, Jeffrey C., Schaub, Robert G., Ikuta, Tohru, Head, C. Alvin · 2011 · Blood
Cited by 144

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Adhesive interactions between circulating sickle red blood cells (RBCs), leukocytes, and endothelial cells are major pathophysiologic events in sickle cell disease (SCD). To develop new therapeutics that efficiently inhibit adhesive interactions, we generated an anti–P-selectin aptamer and examined its effects on cell adhesion using knockout-transgenic SCD model mice. Aptamers, single-stranded oligonucleotides that bind molecular targets with high affinity and specificity, are emerging as new therapeutics for cardiovascular and hematologic disorders. In vitro studies found that the anti–P-selectin aptamer exhibits high specificity to mouse P-selectin but not other selectins. SCD mice were injected with the anti–P-selectin aptamer, and cell adhesion was observed under hypoxia. The anti–P-selectin aptamer inhibited the adhesion of sickle RBCs and leukocytes to endothelial cells by 90% and 80%, respectively. The anti–P-selectin aptamer also increased microvascular flow velocities and reduced the leukocyte rolling flux. SCD mice treated with the anti–P-selectin aptamer demonstrated a reduced mortality rate associated with the experimental procedures compared with control mice. These results demonstrate that anti–P-selectin aptamer efficiently inhibits the adhesion of both sickle RBCs and leukocytes to endothelial cells in SCD model mice, suggesting a critical role for P-selectin in cell adhesion. Anti–P-selectin aptamer may be useful as a novel therapeutic agent for SCD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-05-285718

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 45

  1. Hebbel, 1980, Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity., N Engl J Med, 302, 992, 10.1056/NEJM198005013021803 · DOI · Paper page
  2. Pan, 1998, Comparison of promoters for the murine and human P-selectin genes suggests species-specific and conserved mechanisms for transcriptional regulation in endothelial cells., J Biol Chem, 273, 10058, 10.1074/jbc.273.16.10058 · DOI
  3. Matsui, 2001, P-selectin mediates the adhesion of sickle erythrocytes to the endothelium., Blood, 98, 1955, 10.1182/blood.V98.6.1955 · DOI · Paper page
  4. Turhan, 2002, Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm., Proc Natl Acad Sci U S A, 99, 3047, 10.1073/pnas.052522799 · DOI · Paper page
  5. Eppihimer, 1996, Heterogeneity of expression of E- and P-selectins in vivo., Circ Res, 79, 560, 10.1161/01.RES.79.3.560 · DOI · Paper page
  6. Kato, 2005, Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality., Br J Haematol, 130, 943, 10.1111/j.1365-2141.2005.05701.x · DOI · Paper page
  7. Blann, 2008, Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease: relationship to genotype., J Thromb Thrombolysis, 25, 185, 10.1007/s11239-007-0177-7 · DOI
  8. Steinberg, 2006, Pathophysiologically based drug treatment of sickle cell disease., Trends Pharmacol Sci, 27, 204, 10.1016/j.tips.2006.02.007 · DOI
  9. Keefe, 2008, Aptamers as candidate therapeutics for cardiovascular indications., Curr Opin Pharmacol, 8, 147, 10.1016/j.coph.2007.12.005 · DOI
  10. Tuerk, 1990, Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase., Science, 249, 505, 10.1126/science.2200121 · DOI · Paper page
  11. Ng, 2006, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease., Nat Rev Drug Discov, 5, 123, 10.1038/nrd1955 · DOI · Paper page
  12. Keefe, 2010, Aptamers as therapeutics., Nat Rev Drug Discov, 9, 537, 10.1038/nrd3141 · DOI · Paper page
  13. Ryan, 1997, Knockout-transgenic mouse model of sickle cell disease., Science, 278, 873, 10.1126/science.278.5339.873 · DOI · Paper page
  14. Diener, 2009, Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779., J Thromb Haemost, 7, 1155, 10.1111/j.1538-7836.2009.03459.x · DOI
  15. Mazo, 1998, Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1., J Exp Med, 188, 465, 10.1084/jem.188.3.465 · DOI · Paper page
  16. Chiang, 2007, Imaging receptor microdomains on leukocyte subsets in live mice., Nat Methods, 4, 219, 10.1038/nmeth1018 · DOI
  17. Lipowsky, 1978, Application of the “two-slit” photometric technique to the measurement of microvascular volumetric flow rates., Microvasc Res, 15, 93, 10.1016/0026-2862(78)90009-2 · doi:10.1016/0026-2862(78)90009-2
  18. Lipowsky, 1980, In vivo measurements of “apparent viscosity” and microvessel hematocrit in the mesentery of the cat., Microvasc Res, 19, 297, 10.1016/0026-2862(80)90050-3 · DOI · Paper page
  19. Becker, 2000, Digital video-imaging of leukocyte migration in the iris: intravital microscopy in a physiological model during the onset of endotoxin-induced uveitis., J Immunol Methods, 240, 23, 10.1016/S0022-1759(00)00165-4 · doi:10.1016/s0022-1759(00)00165-4
  20. French, 1997, Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition., Blood, 89, 4591, 10.1182/blood.V89.12.4591 · DOI · Paper page
  21. Kaul, 2000, Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice., J Clin Invest, 106, 411, 10.1172/JCI9225 · DOI · Paper page
  22. Setty, 1996, Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease., Blood, 88, 2311, 10.1182/blood.V88.6.2311.bloodjournal8862311 · DOI · Paper page
  23. Russell, 2003, Low venular shear rates promote leukocyte-dependent recruitment of adherent platelets., Am J Physiol Gastrointest Liver Physiol, 284, G123, 10.1152/ajpgi.00303.2002 · DOI · Paper page
  24. Turhan, 2004, Intravenous immune globulin prevents venular vaso-occlusion in sickle cell mice by inhibiting leukocyte adhesion and the interactions between sickle erythrocytes and adherent leukocytes., Blood, 103, 2397, 10.1182/blood-2003-07-2209 · DOI · Paper page
  25. Finnegan, 2007, Small-molecule cyclic alpha V beta 3 antagonists inhibit sickle red cell adhesion to vascular endothelium and vasoocclusion., Am J Physiol Heart Circ Physiol, 293, H1038, 10.1152/ajpheart.01054.2006 · DOI
  26. Lutty, 2002, Mechanisms for sickle red blood cell retention in choroid., Curr Eye Res, 25, 163, 10.1076/ceyr.25.3.163.13481 · DOI
  27. Hebbel, 2004, The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy., Microcirculation, 11, 129, 10.1080/mic.11.2.129.151 · doi:10.1080/mic.11.2.129.151 · Paper page
  28. McEver, 1995, Leukocyte trafficking mediated by selectin-carbohydrate interactions., J Biol Chem, 270, 11025, 10.1074/jbc.270.19.11025 · DOI · Paper page
  29. Varki, 1997, Selectin ligands: will the real ones please stand up?, J Clin Invest, 100, S31
  30. Nelson, 1993, Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation., Blood, 82, 3253, 10.1182/blood.V82.11.3253.3253 · DOI · Paper page
  31. Wautier, 1986, Release of prostacyclin after erythrocyte adhesion to cultured vascular endothelium., J Lab Clin Med, 107, 210
  32. Wick, 1987, Unusually large von Willebrand factor multimers increase adhesion of sickle erythrocytes to human endothelial cells under controlled flow., J Clin Invest, 80, 905, 10.1172/JCI113151 · DOI
  33. Sugihara, 1992, Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells., Blood, 80, 2634, 10.1182/blood.V80.10.2634.2634 · DOI · Paper page
  34. Swerlick, 1993, Alpha 4 beta 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium., Blood, 82, 1891, 10.1182/blood.V82.6.1891.1891 · DOI · Paper page
  35. Udani, 1998, Basal cell adhesion molecule/lutheran protein. The receptor critical for sickle cell adhesion to laminin., J Clin Invest, 101, 2550, 10.1172/JCI1204 · DOI · Paper page
  36. Chang, 2008, Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion., Blood, 111, 915, 10.1182/blood-2007-04-084061 · DOI · Paper page
  37. Francis, 1992, Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease., J Natl Med Assoc, 84, 611
  38. Wagner, 2008, The vessel wall and its interactions., Blood, 111, 5271, 10.1182/blood-2008-01-078204 · DOI · Paper page
  39. Orbach, 2004, Intravenous immunoglobulin and the kidney–a two-edged sword., Semin Arthritis Rheum, 34, 593, 10.1016/j.semarthrit.2004.06.003 · DOI
  40. Pendergrast, 2005, Nucleic acid aptamers for target validation and therapeutic applications., J Biomol Tech, 16, 224
  41. Okpala, 2006, Leukocyte adhesion and the pathophysiology of sickle cell disease., Curr Opin Hematol, 13, 40, 10.1097/01.moh.0000190108.62414.06 · DOI
  42. Gilbert, 2007, First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers., Circulation, 116, 2678, 10.1161/CIRCULATIONAHA.107.724864 · DOI · Paper page
  43. Knobl, 2009, Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura., Transfusion, 49, 2181, 10.1111/j.1537-2995.2009.02232.x · doi:10.1111/j.1537-2995.2009.02232.x
  44. Dyke, 2006, First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity., Circulation, 114, 2490, 10.1161/CIRCULATIONAHA.106.668434 · DOI · Paper page
  45. Chan, 2008, A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor., J Thromb Haemost, 6, 789, 10.1111/j.1538-7836.2008.02932.x · DOI

Cited by

See all 144

Metadata

Authors
Gutsaeva, D. R., Parkerson, J. B., Yerigenahally, S. D., Kurz, J. C., Schaub, R. G., Ikuta, T., & Head, C. A.
Venue
Blood
Published
2011-01-13
Volume
117
Issue
2
Pages
727-735
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2002783428
Cited by
144
References
4
FWCI
3.63
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. https://app.cochat.ai/papers/10.1182/blood-2010-05-285718
The paper
Gutsaeva, D. R., Parkerson, J. B., Yerigenahally, S. D., Kurz, J. C., Schaub, R. G., Ikuta, T., & Head, C. A. (2011). Inhibition of cell adhesion by anti–P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood. https://doi.org/10.1182/blood-2010-05-285718

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.